Medically reviewed by Doru Paul, MD Key Takeaways A JAK2 mutation can make your body produce too many blood cells.  JAK2 ...

Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial. A ...